Nicotine is usually discussed as an addictive drug. But in 1959, researchers noticed something unexpected: people who smoked appeared less likely to develop Parkinson’s disease. That observation survived decades of scrutiny and eventually led to animal experiments, memory studies, nicotine patches, and major clinical trials. This investigation follows that evidence from the original anomaly to the latest human research to determine what nicotine actually does to the brain—and whether its neuroprotective reputation has been earned.

IN THIS INVESTIGATION

How researchers first uncovered the strange relationship between smoking and Parkinson’s disease.

Why the association persisted across decades of observational research.

What nicotine appeared to do in laboratory models of dopamine-neuron damage.

How early experiments moved nicotine into research on memory, Alzheimer’s disease, and cognitive impairment.

What happened when nicotine was tested in people already living with Parkinson’s disease.

Why short-term cognitive enhancement, disease treatment, and disease prevention are three fundamentally different claims.

What the major human trials can—and cannot—tell us about nicotine and the brain.

Time Stamps

0:00 – Intro
1:44 – Reverse causation theory
2:32 – The Swedish snus study
4:00 – Animal trials: mice vs. monkeys
5:16 – Nicotine's effect on the brain
7:35 – The NIC-PD trial
9:04 – The MIND trial
11:31 – The 2009 paper that predicted the failure
12:55 – What the evidence actually shows

REFERENCES

Dorn HF. Tobacco consumption and mortality from cancer and other diseases. Public Health Rep. 1959;74(7):581–593.

Kessler II, Diamond EL. Epidemiologic studies of Parkinson’s disease. I. Smoking and Parkinson’s disease: a survey and explanatory hypothesis. Am J Epidemiol. 1971;94(1):16–25.

Li X, et al. Association between cigarette smoking and Parkinson’s disease: a meta-analysis. Arch Gerontol Geriatr. 2015;61(3):510–516. PMID 26272284.

Gallo V, et al. Exploring causality of the association between smoking and Parkinson’s disease. Int J Epidemiol. 2019;48(3):912–925.

Mappin-Kasirer B, et al. Tobacco smoking and the risk of Parkinson disease: a 65-year follow-up of 30,000 male British doctors. Neurology. 2020;94(20):e2132–e2138. PMID 32371450. DOI 10.1212/WNL.0000000000009437.

Yang F, Pedersen NL, Ye W. Swedish snus and the risk of Parkinson’s disease: a pooled analysis of seven prospective studies. Int J Epidemiol. 2017;46(3):872–880. PMID 27940486. DOI 10.1093/ije/dyw294.

Nielsen SS, et al. Nicotine from edible Solanaceae and risk of Parkinson disease. Ann Neurol. 2013;74(3):472–477. PMID 23661325.

Ma C, et al. Dietary nicotine intake and risk of Parkinson disease: a prospective study. Am J Clin Nutr. 2020;112(4):1080–1087. PMID 32725131.

Quik M, et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem. 2006;98(6):1866–1875. PMID 16882311.

Huang LZ, Parameswaran N, Bordia T, McIntosh JM, Quik M. Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. J Neurochem. 2009;109(3):826–837. PMID 19250334. DOI 10.1111/j.1471-4159.2009.06011.x.

Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210(4):453–469. PMID 20414766. DOI 10.1007/s00213-010-1848-1.

Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson’s disease. Mov Disord. 2012;27(8):947–957.

Newhouse PA, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012;78(2):91–101. PMID 22232050. DOI 10.1212/WNL.0b013e31823efcbb.

Oertel WH, et al. Transdermal nicotine treatment in early Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. PMID 38320207. http://ClinicalTrials.gov : NCT01560754.

Villafane G, et al. High-dose transdermal nicotine in Parkinson’s disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study. Eur J Neurol. 2018;25(1):120–127.

Memory Improvement Through Nicotine Dosing study. Two-year randomized trial of transdermal nicotine in mild cognitive impairment. CTAD 2025 official results presentation. http://ClinicalTrials.gov : NCT02720445. Primary results had not yet been published in a peer-reviewed paper when the episode research was locked.